Cas9 Stable Cell Line - MC38

The MC38 cell line is a mouse colon adenocarcinoma model derived from C57BL/6 mice. Due to its potent tumorigenicity and immunogenicity, it is widely recognized in preclinical cancer research. As a homologous cell line, MC38 can stably form tumors in immunocompetent normal mice, thus possessing significant value in studying tumor-immune interactions, immunotherapy efficacy, and metastasis. The Cas9 Stable Cell Line - MC38 is a genetically engineered variant in which CRISPR-associated protein 9 (Cas9) is stably integrated into the MC38 genome. This modification allows for precise targeted genome editing without repeated transfections because the cells constitutively express the Cas9 nuclease. This cell line ensures stable Cas9 expression and retains key characteristics of the parental MC38, including rapid proliferation, epithelial cell morphology, and sensitivity to immune checkpoint inhibitors.

The Cas9 Stable Cell Line - MC38 is widely used in various applications in oncology and immunology research. It serves as a powerful platform for functional genomics, supporting high-throughput screening to identify genes crucial for tumor growth, metastasis, or immune escape. Researchers have used this cell line to construct homologous knockout models of specific oncogenes (such as Kras and Myc) or tumor suppressor genes (such as P53) to conduct research on carcinogenesis mechanisms and drug resistance. In immunotherapy development, this cell line facilitates research on these pathways by constructing precise gene perturbations to assess the impact of immune checkpoint pathways (such as PD-1/PD-L1 or CTLA-4) on T cell activation and tumor clearance.